Dextromethorphan Metabolic Lifetime Extension via CYP2D6 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dextromethorphan has limited systemic drug exposure in extensive metabolizers due to rapid hepatic metabolism, limiting its clinical utility as a single agent for neurological disorders.
Innovation Solution
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit its metabolism, increasing plasma levels and metabolic lifetime, thereby enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dextromethorphan is administered alone, then it provides cough suppression and neurological effects, but rapid hepatic metabolism limits plasma levels and therapeutic efficacy in extensive metabolizers
Solution Approach 1:
The patent introduces bupropion and its metabolites (hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion) as intermediary substances that inhibit CYP2D6 enzyme activity. These intermediaries block the metabolic pathway of dextromethorphan, preventing its rapid conversion to dextrorphan and other metabolites, thereby extending dextromethorphan's plasma half-life and enhancing its therapeutic effects without requiring direct modification of dextromethorphan itself.
2Productivity
If dextromethorphan is administered to extensive metabolizers, then rapid metabolism occurs, but this results in limited systemic drug exposure and reduced clinical utility
Solution Approach 1:
The patent converts the harmful effect of rapid metabolism (which causes low systemic exposure) into a beneficial outcome by co-administering CYP2D6 inhibitors. The same metabolic pathway that rapidly clears dextromethorphan is blocked by bupropion metabolites, transforming the extensive metabolizer phenotype from a disadvantage into an opportunity for controlled, sustained drug release and enhanced therapeutic effect through inhibitor-mediated metabolism modulation.
3Reliability
If dextromethorphan is given frequently to maintain plasma levels, then therapeutic efficacy improves, but dosing frequency increases and convenience decreases
Solution Approach 1:
The patent employs preliminary action by co-administering or pre-administering CYP2D6 inhibitors (bupropion or its metabolites) before or with dextromethorphan. This preliminary inhibition of the metabolic enzyme creates a protective effect that sustains dextromethorphan plasma levels over an extended period, allowing less frequent dosing intervals while maintaining therapeutic efficacy. The inhibitor is already in place to prevent rapid metabolism before dextromethorphan is fully cleared.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach increases dextromethorphan plasma levels, allowing for less frequent dosing without loss of efficacy and improving therapeutic properties for neurological disorders, including cough suppression and pain management.
Implementation Method 1
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit its metabolism
Data Source
AI summary
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed